149 results about "Arginase" patented technology

The invention features methods and compositions for diagnosis and treatment of conditions associated with decreased nitric oxide bioavailability, such as a condition associated with elevated arginase activity, using an arginine- and/or arginase-inhibitor based therapy, which therapies include administration of arginine or an arginase inhibitor, either alone or in combination. The invention also contemplates administration of magnesium with arginine, an arginase inhibitor, or with arginine-arginase inhibitor combination therapy. The invention also features methods and compositions for diagnosis, including prognosis, of conditions associated with arginase activity by assessing the ratio of arginine to ornithine in samples from a subject.

The invention belongs to the field of medicine and biotechnology, and relates to a synergistic drug compound for treating tumors and a preparation method thereof. The drug compound is composed of one or more cell autophagy inhibitors and arginase, especially human recombinant Arginase is made into a synergistic drug compound for treating tumors, and the synergistic drug compound can inhibit autophagy by inhibiting autophagy through autophagy inhibitors to increase tumor cells' ability to arginase. sensitivity, and enhance the therapeutic effect of arginase, especially human recombinant arginase, on tumors, especially triple-negative breast cancer cells. The drug compound of the present invention can be used for clinical treatment of breast cancer, melanoma, lung cancer, brain tumor, lymphoma, leukemia and myeloma.

A method for preparing D-arginine hydrochloride and L-ornithine hydrochloride by splitting DL-arginine by microbial enzymatic method. The present invention utilizes the fermented bacterium of recombinant E. coli or its spray-dried preparation that highly expresses L-arginase as an enzyme source, uses DL-arginine as a substrate, and splits DL-arginine through an enzymatic reaction to produce D-arginine and L-ornithine. The resulting liquid is converted into L-ornithine monohydrochloride by adding hydrochloric acid, then adding a certain volume of ethanol to precipitate it, and collecting the precipitate to obtain L-ornithine hydrochloride; in the supernatant, D- The purification method of arginine is: adsorption and elution of ion exchange resin, concentration and drying under reduced pressure, to obtain D-arginine hydrochloride; this patent provides a new D-arginine hydrochloride and L- Green production process route of ornithine hydrochloride.

The present invention provides an isolated and substantially purified recombinant human arginase having sufficiently high enzymatic activity and stability to maintain Adequate Arginine Depletion in a patient. The present invention also provides a pharmaceutical composition comprising the modified invention enzyme and method for treatment of diseases using the pharmaceutical composition.

The invention discloses a double-stained kit for auxiliary diagnosis of benign or malignant hepatocellular tumor and application thereof. The kit comprises the following components: mixed primary antibody of Arginase-1 and Glypian-3, mixed second antibody of alkaline phosphatase conjugated goat anti-rabbit second antibody and horse radish peroxidase labeled goat anti -mouse second antibody, chromogenic reagent AP-Red and DAB (Diaminobenzidine), and TBS (Tris buffer saline) buffer solution. Two immunohistochemical labels provided by the invention are used for auxiliary diagnosis of benign or malignant hepatocellular tumor and differentiation degrees of tumor, the two labels are displayed through staining label by different detection systems and utilizing the differences of target cells stained by each label, information quantity and differential staining on the same radiograph are improved, readability and accuracy of radiograph reading are increased, so that the double-stained kit has important significance to identification of benign or malignant hepatocellular tumor and differentiation degrees of tumor.

The invention relates to a method for preparing L-ornithine-L-aspartate salt. The L-ornithine-L-aspartate salt is produced through conversion of arginase. The method comprises the following process steps of: (1) preparing immobilized enzyme; (2) optimizing conversion conditions; and (3) extracting product and refining. Compared with the prior art, the method has the advantages that: production cost is low, the production conditions are mild, impurities in a conversion system are a few, the process steps are simple, the production operation is safe, the purity is high, 300 to 320g of L-ornithine-L-aspartate salt is contained in each liter of reaction solution, the yield is high, the conversion rate of arginase is over 95 percent and the like.

The invention discloses a breeding method for arginase transgenic corn, which comprises the steps of cloning ZmArg genes in the corn, converting an extremely early selfing line of the corn by an agrobacterium mediation method, and creating a high-yield new corn germplasm. With the method, the high-efficiency extraneous ZmArg genes are transplanted into the selfing line of the corn and expressed successfully; the arginase levels in various growth periods of the corn are raised to some extent; and yield traits such as thick corncobs, long niblets and wide niblets are correspondingly improved.

Methods and composition for generation of arginase variants with high serum persistence are provided. For example, in certain aspects methods for purifying pegylated arginase are described. Furthermore, the invention provides stabilized arginase multimers or pharmaceutical composition thereof.

The invention relates to a preparation method for L-ornithine hydrochloride. The L-ornithine hydrochloride is produced through converting arginase. The method comprises the following technological steps: (1) preparing immobilized enzyme; (2) optimizing conversion conditions; and (3) extracting products and refining. Compared with the prior art, the invention has the advantages that the production cost is low, the production conditions are mild, the impurities in the conversion system are less, the technological steps are simple, the production and the operation are safe, the purity is high, one liter of solution contains 100-130g of L-ornithine hydrochloride, the yield is high, the conversion rate of arginine reaches more than 95 percent and the like.

The invention provides a method for displaying human arginase1 on surfaces of escherichia coli. The method comprises steps as follows: 1) recombinant plasmids for surface display of human arginase1 are constructed; 2) the recombinant plasmids are converted into escherichia coli competent cells, and genetic engineering strains are obtained; 3) the recombinant strains are subjected to shake-flask culture, and the display efficiency and enzyme activity of human arginase1 are detected; 4) L-Arginine (L-arginine, L-Arg) is efficiently converted by means of the recombinant strains for synthesis of L-Ornithine (L-ornithine, L-Orn). Human arginase1 is effectively displayed on surfaces of escherichia coli cells through improved Type V self-transport protein (Antigen 43), and industrial application of human arginase1 is realized more rapidly. By comparison with an original Type V self-transport protein (Antigen 43) display system, the display efficiency and the enzyme activity of human arginase1 are remarkably improved; by comparison with an existing chitin immobilization method, the synthesis cost is reduced, the technological process is shortened, and the purification procedures are simplified.

The invention belongs to the field of bio-techniques and particularly relates to an enzymatic conversion method of L-ornithine. The method includes: adding bacterial cells of arginase activity or crude enzyme extract into liquor containing arginine, or crude arginine, or crude arginine salt, serving as substrate preparation enzyme conversion liquid, allowing enzymatic reaction at 25 DEG C to 55 DEG C under pH of 7 to 11, and performing separation by the combination of isoelectric point crystallization and ion exchanging so as to obtain a conversion product, L-ornithine salt. The method has the advantages such that the L-ornithine salt of high added value is synthesized by a substrate enzymatic method with the low-cost L-ornithine liquor, the range of material sources is wide, enzymatic reaction is efficient, operating is convenient, and production cost is low.

The present invention relates to genes, proteins and methods comprising molecules that alter amino acid levels. In one embodiment, the present invention relates to altering guanidino substrate hydrolysis activities in plants, arthropods and microorganisms using molecules within the arginase family and other molecules that alter an amino acid levels. In ones embodiment, the present invention relates to altering threonine substrate deamination and dehydration activities in plants, arthropods and microorganisms using molecules within the threonine deaminase family and other molecules that alter amino acid levels. In one embodiment, the present invention relates to using genes, proteins and methods comprising arginase or threonine deaminase for altering the pathophysiology of plants, arthropods and microorganisms. In a preferred embodiment, the present invention relates to altering guanidino substrate hydrolysis activity in plants, arthropods, and microorganisms using arginase. In another preferred embodiment, the invention relates to altering threonine substrated deamination and dehydration activity in plants, arthropods, and microorganisms using threonine deaminase. In some embodiments, the invention related to overexpression and increased activity of arginase, threonine deaminase and a proteinase inhibitor.

The present invention relates to a preparation method for L-ornithine-alpha-ketoglutarate. The L-ornithine-alpha-ketoglutarate is produced by arginase transformation. The preparation method comprises the following steps: (1) preparation of immobilized enzyme; (2) optimization of transformation conditions; (3) product extraction and refining process. Compared to the prior art, the preparation method of the present invention has the following advantages that: the preparation method of the present invention has characteristics of low production cost, mild production conditions, less impurities in the transformation system, simple process steps, safe production operation and high purity; qualified products meeting the light transmission requirements can be synthesized; each liter of the reaction solution contains 300-320 g of the L-ornithine-alpha-ketoglutarate, and the transformation efficiency of the alpha-ketoglutaric acid is more than 90%; the preparation method further has other advantages.

The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.

The invention belongs to the field of gene engineering, which relates to a recombinant human arginase fusion protein and application thereof. The recombinant human arginase fusion protein is a recombinant human arginase fusing any one polypeptide with an amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. The fusion protein can effectively achieve the enrichment of drug in the tumor site and prevent homeostatic mechanism of amino acid to a certain degree so as to obtain good therapeutic effect.